Insider · CIK 0001861550

Lorrain Daniel S.

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001861550

Forms 4 and 5

Insider transactions

44 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-09	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+25 sh	$1.01	+$25.25	135,227
2026-07-09	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−25 sh	$16.00	−$400	135,202
2026-07-09	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−25 sh	—	—	33,257
2026-07-08	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,015 sh	—	—	33,282
2026-07-08	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,015 sh	$1.01	+$1,025.15	136,217
2026-07-08	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,015 sh	$16.00	−$16.2K	135,202
2026-07-01	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−4,183 sh	—	—	34,297
2026-07-01	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+4,183 sh	$1.01	+$4,224.83	143,555
2026-07-01	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−5,852 sh	$15.67	−$91.7K	137,703
2026-07-01	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−2,501 sh	$16.24	−$40.6K	135,202
2026-06-30	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−28.8K sh	—	—	38,480
2026-06-30	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+28.8K sh	$1.01	+$29.1K	168,198
2026-06-30	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−28.8K sh	$16.04	−$462K	139,372
2026-06-01	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,170 sh	$13.16	−$54.9K	139,372
2026-05-01	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,870 sh	$13.06	−$50.5K	143,842
2026-05-01	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−300 sh	$13.84	−$4,152	143,542
2026-04-06	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,170 sh	$13.43	−$56K	147,712
2026-03-02	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,170 sh	$15.01	−$62.6K	151,882
2026-02-25	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,824 sh	$1.01	+$3,862.24	159,876
2026-02-25	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,824 sh	$16.01	−$61.2K	156,052
2026-02-25	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,824 sh	—	—	67,306
2026-02-24	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,300 sh	$16.03	−$68.9K	156,052
2026-02-24	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+4,300 sh	$1.01	+$4,343	160,352
2026-02-24	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−4,300 sh	—	—	71,130
2026-02-19	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+100 sh	$1.01	+$101	156,152
2026-02-19	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−100 sh	—	—	75,430
2026-02-19	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−100 sh	$16.00	−$1,600	156,052
2026-02-11	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−400 sh	—	—	75,530
2026-02-11	CTNMContineum Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+400 sh	$1.01	+$404	156,452
2026-02-11	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−400 sh	$16.00	−$6,400	156,052
2026-02-03	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,170 sh	$15.25	−$17.8K	156,052
2026-02-03	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$14.82	−$44.5K	157,222
2026-01-30	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+160K sh	—	—	160,000
2026-01-30	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+6,500 sh	—	—	6,500
2026-01-05	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,670 sh	$10.35	−$38K	160,722
2026-01-05	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−500 sh	$11.13	−$5,564.9	160,222
2025-12-23	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,170 sh	$12.23	−$51K	164,392
2025-01-31	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+110K sh	—	—	110,000
2025-01-31	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+3,700 sh	—	—	3,700
2024-11-25	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,010 sh	$16.02	−$16.2K	168,562
2024-11-18	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−99 sh	$17.05	−$1,687.95	169,572
2024-11-18	CTNMContineum Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−6,091 sh	$16.37	−$99.7K	169,671
2024-05-24	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+3,700 sh	—	—	3,700
2024-05-24	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Jul 104
Lorrain Daniel S.0001628280-26-047909
SEC(opens sec.gov)
Jul 24
Lorrain Daniel S.0001628280-26-047058
SEC(opens sec.gov)
Jun 14
Lorrain Daniel S.0001628280-26-039641
SEC(opens sec.gov)
May 14
Lorrain Daniel S.0001628280-26-029435
SEC(opens sec.gov)
Apr 64
Lorrain Daniel S.0001628280-26-023949
SEC(opens sec.gov)
Mar 24
Lorrain Daniel S.0001437749-26-006422
SEC(opens sec.gov)
Feb 264
Lorrain Daniel S.0001437749-26-005889
SEC(opens sec.gov)

Companies

Contineum Therapeutics, Inc.Chief Scientific OfficerCTNM

Address

3565 GENERAL ATOMICS COURT, SUITE 200

SAN DIEGO, CA, 92121